(Q37314520)

19 August 2017

1 reference

title

Platinum compounds 30 years after the introduction of cisplatin: implications for the treatment of ovarian cancer (English)

1 reference

19 August 2017

1 reference

1 reference

1 reference

1

1 reference

PubMed ID

18977023

19 August 2017

language of work or name

English

0 references

publication date

31 October 2008

1 reference

19 August 2017

1 reference

19 August 2017

112

1 reference

19 August 2017

1

1 reference

19 August 2017

275-281

1 reference

Cis-diamminedichloroplatinum (II). A new anticancer drug

19 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.09.034

Platinums: extending their therapeutic spectrum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.09.034

Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.09.034

Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1-mutated basal-like breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.09.034

How do real tumors become resistant to cisplatin?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.09.034

Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.09.034

Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.09.034

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.09.034

The novel poly(ADP-Ribose) polymerase inhibitor, AG14361, sensitizes cells to topoisomerase I poisons by increasing the persistence of DNA strand breaks.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.09.034

Sequences of topotecan and cisplatin: phase I, pharmacologic, and in vitro studies to examine sequence dependence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.09.034

In vitro and in vivo interaction between cisplatin and topotecan in ovarian carcinoma systems

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.09.034

Tolerance and activity of oxaliplatin with protracted topotecan infusion in patients with previously treated ovarian cancer. A phase I study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.09.034

ATM activation and histone H2AX phosphorylation as indicators of DNA damage by DNA topoisomerase I inhibitor topotecan and during apoptosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.09.034

Platinum anticancer drug damage enforces a particular rotational setting of DNA in nucleosomes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.09.034

The copper influx transporter human copper transport protein 1 regulates the uptake of cisplatin in human ovarian carcinoma cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.09.034

Copper transporters regulate the cellular pharmacology and sensitivity to Pt drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.09.034

Cisplatin rapidly down-regulates its own influx transporter hCTR1 in cultured human ovarian carcinoma cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.09.034

Pharmacological and physiological functions of the polyspecific organic cation transporters: OCT1, 2, and 3 (SLC22A1-3).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.09.034

Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.09.034

Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.09.034

Sequential single agents as first-line chemotherapy for ovarian cancer: a strategy derived from the results of GOG-132.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.09.034

Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.09.034

A systematic review of platinum and taxane resistance from bench to clinic: an inverse relationship

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.09.034

Hexamethylmelamine in platinum-resistant ovarian cancer: how active?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.09.034

Part II: chemotherapy for epithelial ovarian cancer-treatment of recurrent disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.09.034

First-line randomized trials: revisiting the Ptolemaic universe

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.09.034

Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group tria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.09.034

Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.09.034

Second-line chemotherapy with pegylated liposomal doxorubicin and carboplatin is highly effective in patients with advanced ovarian cancer in late relapse: a GINECO phase II trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.09.034

Prolonged topotecan infusion with cisplatin in the first-line treatment of ovarian cancer: an NYGOG and ECOG study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.09.034

Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.09.034

Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the G

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.09.034

Intraperitoneal cisplatin and paclitaxel in ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.09.034

What is the optimal approach to the administration of intraperitoneal chemotherapy in ovarian cancer?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.09.034

National Cancer Institute-United States strategy regarding intraperitoneal chemotherapy for ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.09.034

Can carboplatin replace cisplatin for intraperitoneal use?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.09.034

Pharmacologic principles of intraperitoneal chemotherapy for the treatment of ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.09.034

Heated intra-operative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: pharmacokinetics and tissue distribution

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.09.034

Oxaliplatin for the treatment of cisplatin-resistant cancer: a systematic review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.09.034

Pilot study of the paclitaxel, oxaliplatin, and cisplatin combination in patients with advanced/recurrent ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.09.034

Oxaliplatin and paclitaxel combination in patients with platinum-pretreated ovarian carcinoma: An investigator-originated compassionate-use experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.09.034

A phase II study of a paclitaxel and oxaliplatin combination in platinum-sensitive recurrent advanced ovarian cancer patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.09.034

Phase II study of pegylated liposomal doxorubicin and oxaliplatin in relapsed advanced ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.09.034

Gemcitabine combined with oxaliplatin (GEMOX) as second-line chemotherapy in patients with advanced ovarian cancer refractory or resistant to platinum and taxane

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.09.034

Phase I-II and pharmacokinetic study of gemcitabine combined with oxaliplatin in patients with advanced non-small-cell lung cancer and ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.09.034

Oxaliplatin plus high-dose leucovorin and 5-fluorouracil (FOLFOX 4) in platinum-resistant and taxane-pretreated ovarian cancer: a phase II study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.09.034

Ecto-calreticulin in immunogenic chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.09.034

Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance responsiveness

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.09.034

Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.09.034

Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.09.034

Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.09.034

Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.09.034

Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.09.034

10.1016/J.YGYNO.2008.09.034

7 January 2021

Identifiers

DOI

1 reference

19 August 2017

1 reference

PubMed ID

18977023